Experience With Bezitramide and Droperidol in the Treatment of Severe Chronic Pain

Admiraal, P.V.; Knape, H; Zegveld, C

doi:10.1097/00132586-197312000-00029

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Admiraal and associates first described the successful use of droperidol for chronic pain patients in 1971 (46,47). There are several human studies that have specifically addressed the analgesic effect of droperidol in the ED for treatment of headache.…”

Section: Clinical Evidencementioning

confidence: 99%

Droperidol Analgesia for Opioid-Tolerant Patients

Richards¹,

Richards²,

Ozery³

et al. 2011

The Journal of Emergency Medicine

View full text Add to dashboard Cite

Section: Clinical Evidencementioning

confidence: 99%

Droperidol Analgesia for Opioid-Tolerant Patients

Richards¹,

Richards²,

Ozery³

et al. 2011

The Journal of Emergency Medicine

View full text Add to dashboard Cite

“…Ramirez et al34 was excluded as it had a retrospective cohort design. Three studies assessed pain in mixed populations, including abdominal, but data for abdominal pain patients was not listed independently 38,47,85. Bertrand et al55 was excluded as they did not clearly describe which urologic procedures were included or whether they were intra-abdominal.…”

Section: Resultsmentioning

confidence: 99%

<p>Neuroleptanalgesia for acute abdominal pain: a systematic review</p>

Miller¹,

Khan²,

A³

et al. 2019

JPR

View full text Add to dashboard Cite

Background Acute abdominal pain (AAP) comprises up to 10% of all emergency department (ED) visits. Current pain management practice is moving toward multi-modal analgesia regimens that decrease opioid use. Objective This project sought to determine whether, in patients with AAP (population), does administration of butyrophenone antipsychotics (intervention) compared to placebo, usual care, or opiates alone (comparisons) improve analgesia or decrease opiate consumption (outcomes)? Methods A structured search was performed in Cochrane CENTRAL, CINAHL, Database of Abstracts of Reviews of Effects, Directory of Open Access Journals, Embase, IEEE-Xplorer, Latin American and Caribbean Health Sciences Literature, Magiran, PubMed, Scientific Information Database, Scopus, TÜBİTAK ULAKBİM, and Web of Science. Clinical trial registries ( ClinicalTrials.gov , World Health Organization International Clinical Trials Registry Platform, and Australian New Zealand Clinical Trials Registry), relevant bibliographies, and conference proceedings were also searched. Searches were not limited by date, language, or publication status. Studies eligible for inclusion were prospective randomized clinical trials enrolling patients (age ≥18 years) with AAP treated in acute care environments (ED, intensive care unit, postoperative). The butyrophenone must have been administered either intravenously or intra-muscularly. Comparison groups included placebo, opiate only, corticosteroids, non-steroidal anti-inflammatory drugs, or acetaminophen. Results We identified 7,217 references. Six studies met inclusion criteria. One study assessed ED patients with AAP associated with gastroparesis, whereas five studies assessed patients with postoperative AAP: abdominal hysterectomy (n=4), sleeve gastrectomy (n=1). Three of four studies found improvements in pain intensity with butyrophenone use. Three of five studies reported no change in postoperative opiate consumption, while two reported a decrease. One ED study reported no change in patient satisfaction, while one postoperative study reported improved satisfaction scores. Both extrapyramidal side effects (n=3) and sedation (n=3) were reported as unchanged. Conclusion Based on available evidence, we cannot draw a conclusion on the efficacy or benefit of neuroleptanalgesia in the management of patients with AAP. However, preliminary data suggest that it may improve analgesia and decrease opiate consumption.

show abstract

“…Bunlara Afyon çiçeği, Uykucu Haşhaş gibi isimler de (15,16). Kronik ağrıların akut alevlenmelerinde ise haloperidol, droperidol gibi sedatif butirofenonler da kullanılmalıdır (17). Özellikle de gençlerde bu grup ilaçlar tedavi amacıyla verildiğinde dahi kötüye kullanımı ve yanlış kullanımı oldukça fazladır.…”

Section: Introductionunclassified

Opioidler, Ağrı, Opioidlerin Suistimali ve Yanlış Kullanımı

Kılıç¹

2017

Osmangazi̇ Journal of Medicine

View full text Add to dashboard Cite

Öz: Opioidler, gelincikgiller familyasından Papaver somniferum'dan (haşhaş bitkisi) elde edilen, narkotik analjezikler olarak da bilinen ilaç gruplarıdır. Güçlü ağrı kesici etkileri olması nedeniyle akut, kronik ve de kanser ağrılarının tedavisinde kullanımları oldukça sıktır. Ancak bağımlılık yapıcı etkileri nedeniyle tedaviye başlama sırasında ve tedavi sürecinde önemli sorunlar ortaya çıkabilmektedir. Bu grup ilaçlar analjezik etkileri dışında öksürük kesici ve antidiyareik olarak da kullanılmaktadır. Opioidlerin özellikle de güçlü etkili olanların, gittikçe artan oranda kötüye kullanımı ve yanlış kullanımı sonucunda istenmeyen durumlarla karşılaşılabilmektedir. Ancak terminal dönem kanser hastalarının ağrı tedavisinde yarar zarar oranlarına bakılarak kullanılmaları gerektiği çok açıktır. Bu grup ilaçların kullanımında bağımlılık, hepatit, HIV enfeksiyonları ve kullanılamadığı durumlarda ise oluşan yoksunluk sendromu çok önemli bir sorun oluşturmaktadır. Son yıllarda özellikle gençlerde ve mahkumlarda suistimalinin ve yanlış kullanımının gittikçe arttığı dikkati çekmektedir. Bu durumlarda kaçınılmaz olunan sonuçlardan ancak ve ancak eğitim ve farkındalıklarla kurtulabiliriz.

show abstract

Experience With Bezitramide and Droperidol in the Treatment of Severe Chronic Pain

Cited by 4 publications

References 0 publications

Droperidol Analgesia for Opioid-Tolerant Patients

Droperidol Analgesia for Opioid-Tolerant Patients

<p>Neuroleptanalgesia for acute abdominal pain: a systematic review</p>

Opioidler, Ağrı, Opioidlerin Suistimali ve Yanlış Kullanımı

Contact Info

Product

Resources

About